X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (106) 106
index medicus (98) 98
oncology (94) 94
female (75) 75
aged (56) 56
middle aged (54) 54
chemotherapy (51) 51
male (48) 48
adult (41) 41
3rd-line therapy (38) 38
cancer (38) 38
treatment outcome (37) 37
3rd-line chemotherapy (34) 34
antineoplastic combined chemotherapy protocols - therapeutic use (34) 34
pharmacology & pharmacy (32) 32
antineoplastic agents - therapeutic use (30) 30
phase-ii trial (29) 29
care and treatment (28) 28
retrospective studies (24) 24
1st-line treatment (23) 23
double-blind (23) 23
3rd-line treatment (22) 22
breast neoplasms - drug therapy (22) 22
cetuximab (22) 22
colorectal cancer (22) 22
colorectal neoplasms - drug therapy (22) 22
drug therapy (22) 22
irinotecan (22) 22
docetaxel (21) 21
metastasis (21) 21
randomized-trial (21) 21
aged, 80 and over (20) 20
gastroenterology & hepatology (20) 20
phase-iii trial (20) 20
helicobacter pylori (19) 19
lung neoplasms - drug therapy (19) 19
oxaliplatin (19) 19
medicine & public health (18) 18
research (18) 18
survival (18) 18
analysis (17) 17
neoplasm metastasis (17) 17
open-label (17) 17
postmenopausal women (17) 17
trial (17) 17
2nd-line treatment (16) 16
efficacy (16) 16
helicobacter infections - drug therapy (16) 16
therapy (16) 16
breast cancer (15) 15
colorectal neoplasms - pathology (15) 15
3rd-line rescue therapy (14) 14
antineoplastic combined chemotherapy protocols - adverse effects (14) 14
camptothecin - analogs & derivatives (14) 14
clarithromycin (14) 14
disease-free survival (14) 14
erlotinib (14) 14
hematology, oncology and palliative medicine (14) 14
lung cancer (14) 14
antineoplastic agents (13) 13
carcinoma, non-small-cell lung - drug therapy (13) 13
eradication (13) 13
health aspects (13) 13
helicobacter pylori - drug effects (13) 13
antimitotic agents (12) 12
bevacizumab (12) 12
drug therapy, combination (12) 12
fluorouracil (12) 12
pharmacology/toxicology (12) 12
phase-ii (12) 12
risk factors (12) 12
survival analysis (12) 12
3rd-line hormonal-therapy (11) 11
amoxicillin (11) 11
camptothecin - administration & dosage (11) 11
cancer research (11) 11
cancer therapies (11) 11
exemestane (11) 11
first-line therapy (11) 11
fluorouracil - administration & dosage (11) 11
growth-factor receptor (11) 11
infection (11) 11
multicenter (11) 11
patients (11) 11
randomized phase-iii (11) 11
targeted therapy (11) 11
triple therapy (11) 11
3rd-line (10) 10
5-fluorouracil (10) 10
androstadienes - therapeutic use (10) 10
anti-bacterial agents - therapeutic use (10) 10
aromatase inhibitors (10) 10
aromatase inhibitors - therapeutic use (10) 10
drug administration schedule (10) 10
kaplan-meier estimate (10) 10
lung cancer, non-small cell (10) 10
lung neoplasms - pathology (10) 10
metastatic colorectal cancer (10) 10
mutation (10) 10
prognosis (10) 10
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Gut, ISSN 0017-5749, 01/2017, Volume 66, Issue 1, pp. 6 - 30
Important progress has been made in the management of Helicobacter pylori infection and in this fifth edition of the Maastricht Consensus Report, key aspects... 
CONTAINING QUADRUPLE THERAPY | C-13-UREA BREATH TEST | LOW-DOSE ASPIRIN | GASTROESOPHAGEAL-REFLUX DISEASE | PROTON-PUMP INHIBITOR | SACCHAROMYCES-BOULARDII SUPPLEMENTATION | GASTRIC-CANCER RISK | CONTAINING TRIPLE THERAPY | GASTROENTEROLOGY & HEPATOLOGY | 3RD-LINE RESCUE THERAPY | PEPTIC-ULCER DISEASE | Humans | Helicobacter Infections - prevention & control | Drug Resistance, Bacterial | Helicobacter Infections - complications | Bismuth - therapeutic use | Microbial Sensitivity Tests | Anti-Bacterial Agents - therapeutic use | Nitroimidazoles - therapeutic use | Helicobacter pylori | Helicobacter Infections - drug therapy | Gastritis - microbiology | Helicobacter Infections - diagnosis | Drug Therapy, Combination | Stomach Neoplasms - diagnosis | Early Detection of Cancer | Risk Factors | Gastrointestinal Microbiome | Fluoroquinolones - therapeutic use | Clarithromycin - therapeutic use | Dyspepsia - microbiology | Gastroscopy | Evidence-Based Medicine | Proton Pump Inhibitors - therapeutic use | Stomach Neoplasms - microbiology | Amoxicillin - therapeutic use | Stomach - microbiology | Practice Guidelines as Topic | Helicobacter infections | Care and treatment | Wellness programs | Usage | Working groups | Systematic review | Staphylococcus infections | Management | Stomach cancer | Delphi method | Meta-analysis | Probiotics | Microbiota | Infectious diseases | Antibiotics | Ulcers | Patient satisfaction | Public health
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 10/2015, Volume 21, Issue 19, pp. 4257 - 4261
Journal Article
PLOS ONE, ISSN 1932-6203, 07/2019, Volume 14, Issue 7, p. e0219622
Objectives SCLC makes up approximately 15% of all lung carcinomas and is characterized by relatively aggressive spread and poorer prognosis compared to other... 
SURVIVAL | AUDIT | IMPACT | 3RD-LINE CHEMOTHERAPY | NEUTROPENIA | MULTIDISCIPLINARY SCIENCES | ETOPOSIDE PLUS CISPLATIN | CLINICAL-TRIALS | OUTCOMES | Antimitotic agents | Chemotherapy | Care and treatment | Patient outcomes | Lung cancer, Small cell | Antineoplastic agents | Statistics | Cancer
Journal Article
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, ISSN 1048-891X, 11/2019, Volume 29, Issue 9, pp. 1396 - 1404
Objective To report results from an integrated efficacy and safety analysis supporting the European Commission's approval of the poly(ADP-ribose) polymerase... 
GERMLINE | 3RD-LINE CHEMOTHERAPY | ovarian cancer | FALLOPIAN-TUBE | PARP | RECURRENT OVARIAN | OLAPARIB MONOTHERAPY | MAINTENANCE THERAPY | OBSTETRICS & GYNECOLOGY | ONCOLOGY | DOUBLE-BLIND | HYPERSENSITIVITY REACTIONS | CARCINOMA
Journal Article
ONCOTARGETS AND THERAPY, ISSN 1178-6930, 2019, Volume 12, pp. 6549 - 6554
Objective: Anlotinib is an oral novel multi-target tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor, fibroblast growth factor... 
lung cancer | PHASE-II TRIAL | MULTICENTER | ONCOLOGY | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | VEGF | safety | anlotinib | efficacy | 3RD-LINE
Journal Article
GASTROENTEROLOGIA Y HEPATOLOGIA, ISSN 0210-5705, 12/2016, Volume 39, Issue 10, pp. 697 - 721
Helicobacter pylori approximately infect 50% of Spanish population and causes chronic gastritis, peptic ulcer and gastric cancer. Until now, three consensus... 
CONTAINING QUADRUPLE THERAPY | Clarithromycin | CONCOMITANT THERAPY | Proton pump | DUODENAL-ULCER | PROTON-PUMP INHIBITOR | BLEEDING PEPTIC-ULCER | SEQUENTIAL THERAPY | Omeprazole | STANDARD TRIPLE THERAPY | Helicobacter pylori | inhibitor | Bismuth | ERADICATION THERAPY | Metronidazole | GASTROENTEROLOGY & HEPATOLOGY | 3RD-LINE RESCUE THERAPY | MAASTRICHT-III CONSENSUS
Journal Article
Annals of Oncology, ISSN 0923-7534, 04/2018, Volume 29, Issue 4, pp. 835 - 856
Journal Article
CANCER TREATMENT REVIEWS, ISSN 0305-7372, 07/2014, Volume 40, Issue 6, pp. 701 - 715
Oxaliplatin, irinotecan and 5-fluorouracil in combination with or without targeted therapies are well-documented treatment options for first- and second-line... 
3RD-LINE CHEMOTHERAPY | Targeted therapy | MITOMYCIN-C | Colorectal cancer | ANTI-EGFR THERAPY | Salvage therapy | Refractory | LIVER METASTASES | K-RAS MUTATIONS | Chemotherapy | PHASE-II TRIAL | HEPATIC ARTERIAL INFUSION | ONCOLOGY | EVERY 2 WEEKS | COMBINATION CHEMOTHERAPY | GROWTH-FACTOR
Journal Article
MEDICINA CLINICA, ISSN 0025-7753, 01/2017, Volume 148, Issue 1, pp. 20 - 22
Journal Article
Journal Article
Journal of Oncology Practice, ISSN 1554-7477, 06/2018, Volume 14, Issue 6, pp. 359 - 366
Despite high response rates to initial therapy, relapses are common in patients with small-cell lung cancer (SCLC). Systemic therapy after first-line failure... 
PHASE-II TRIAL | MULTICENTER | 3RD-LINE CHEMOTHERAPY | MANAGEMENT | ONCOLOGY | TOPOTECAN | AMERICAN-COLLEGE | 2ND-LINE CHEMOTHERAPY | IRINOTECAN | OPEN-LABEL | TEMOZOLOMIDE
Journal Article